Akadeum Life Sciences, Inc.

Akadeum Life Sciences, Inc. is a US-based company focused on developing advanced cell separation technologies, particularly through their innovative Alerion™ Microbubble Cell Separation System, which enhances cell therapy manufacturing efficiency. Founded in 2014 and headquartered in Ann Arbor, US, Akadeum Life Sciences specializes in cell separation technologies. The company is led by founder and CEO Brandon Mcnaughton, who has a history of entrepreneurial ventures.

Akadeum has raised USD 20. 00 mn in their latest funding round on June 4, 2025, led by Michigan Capital Network, with participation from Arboretum Ventures and NYBC Ventures. The company has completed a total of 8 deals. Akadeum Life Sciences specializes in innovative cell separation technologies, with a primary focus on its flagship product, the Alerion™ Microbubble Cell Separation System.

This system employs a unique microbubble technology that enhances the efficiency of cell therapy manufacturing by improving cell viability, purity, and recovery rates. The microbubble kits are designed to seamlessly integrate into existing laboratory workflows, facilitating the rapid isolation of target cells with minimal footprint reduction of up to 42%. The end-use cases for these technologies are particularly relevant to researchers and companies in the fields of cell therapy and immunology, where high-quality cell samples are critical for therapeutic applications. Akadeum's products serve a diverse client base that includes research institutions, biotech companies, and pharmaceutical firms primarily located in North America and Europe, enabling advancements in treatments such as CAR T-cell therapy and other regenerative medicine applications.

While specific financial data is not disclosed, Akadeum Life Sciences operates on a B2B sales model, primarily engaging with research institutions and commercial partners to distribute its cell separation kits. Transactions are typically structured around direct sales, where clients procure products based on their research requirements. Revenue generation is bolstered through partnerships that facilitate the use of Akadeum's technology in broader applications across the life sciences sector. Specific pricing plans and product costs associated with the Alerion™ system and other microbubble kits are determined through client negotiations and are tailored to individual project needs.

This approach fosters ongoing relationships with existing customers while attracting new clients interested in improving their cell therapy processes. In June 2025, Akadeum Life Sciences, Inc. raised USD 20. 00 mn in Series A funding, which will be utilized for further growth and development.

The company plans to launch upcoming products designed to enhance their cell separation technology, with specific timelines yet to be announced. Additionally, Akadeum aims to expand its reach into new markets, focusing on both North America and Europe, by the end of 2025, to better serve researchers and companies in cell therapy and immunology.